Wockhardt Limited has now engaged multiple USFDA approved manufacturing partners, after thorough due diligence and inspection of their facilities, to manufacture various products of the company for sale in US/North America under the same brand and Wockhardt name.

Further, the company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner and in full compliance with the applicable local laws.

The company believes, that this new arrangement is in the best interest of the company as this will help the company to avoid the manufacturing and quality management cost completely resulting in significant savings in operating and overhead cost while allowing the management to completely focus on penetrating and expansion of the market share of its products in US/North America.

The management emphasizes that the above closure of the manufacturing unit will not affect the availability of its products in the US market in view of the alternate arrangement already put in place and on the contrary allow the company to grow more vigorously in the US market.

In view of the changed pharmaceutical market situation in the United States, the management of Wockhardt Limited had initiated various cost optimisation measures, including restructuring its USA business model, inter alia, by closing down its manufacturing facility in Illinois, USA and undertaking its business in USA through contract manufacturing the products sold by it in US/North America by engaging USFDA approved manufacturing partners meeting the superior quality standards acceptable to the company.